Compare MBAI & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBAI | ENSC |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 7.6M |
| IPO Year | 2014 | 2017 |
| Metric | MBAI | ENSC |
|---|---|---|
| Price | $6.30 | $0.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 61.4K | ★ 2.0M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.24 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,066,650.00 |
| Revenue This Year | N/A | $55.01 |
| Revenue Next Year | N/A | $1,033.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.95 | $0.23 |
| 52 Week High | $10.21 | $2.75 |
| Indicator | MBAI | ENSC |
|---|---|---|
| Relative Strength Index (RSI) | 58.95 | 67.04 |
| Support Level | $1.19 | $0.47 |
| Resistance Level | $10.21 | $0.61 |
| Average True Range (ATR) | 0.37 | 0.04 |
| MACD | -0.31 | 0.00 |
| Stochastic Oscillator | 11.04 | 83.06 |
MBody AI Ltd is an embodied artificial intelligence company. Its core technology is the MBody AI Orchestrator (Orchestrator), a proprietary, hardware-agnostic software platform that serves as an intelligence layer designed to enable autonomous systems to operate, coordinate, and improve more effectively. MBody AI does not manufacture robots; it makes third-party robots more intelligent and coordinated through the Orchestrator and deploys them at customer sites together with its software and related services. Each deployment is designed to generate proprietary operational data. Its initial commercial focus is the hospitality industry, with potential applications across other labor-intensive sectors, including warehousing, office management, and healthcare.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.